戻る Agenda
Implementing an Internationally Acceptable Framework for the Benefit-risk Assessment of Medicines: How Close Are We to This?
Session Chair(s)
Stuart Russel Walker, PHD
Professor and Consultant
Centre for Innovation In Regulatory Science (CIRS), United Kingdom
Quantitative Benefit-risk Assessment: Where Are We Now, Why the Resistance and Where Are We Going?
Learning Objective : Evaluate the progress on the implementation of benefit-risk methodologies within companies and agencies; Discuss assessing relative importance (weighting) and uncertainty within the context of making explicit benefit-risk decisions and how these should be approached within the framework.
Speaker(s)
Benefit-Risk Framework Study: Can This Improve Regulatory Decision Making?
James Leong, PHD, MPHARM
Duke NUS Medical School, Singapore
Head,Health Products & Regulatory Science Centre of Regulatory Excellence (CoRE)
PDUFA V Implementation Plan for a Structured Approach to Benefit-risk Assessment
Nate C. Blevins, MS
GlaxoSmithKline, United States
R&D IT Program Manager
Quantitative Benefit-risk Assessment: Where Are We Now, Why the Resistance and Where Are We Going?
Lawrence Phillips, PHD
London School of Economics, United Kingdom
Emeritus Professor of Decision Sciences, Department of Management